Publications (17) Publications in which a researcher has participated

2016

  1. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122

  2. Albumin-Bound (NAB) Paclitaxel, Abraxane®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 7-17

  3. Docetaxel.Taxotere®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 139-145

  4. Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy

    BMC Cancer, Vol. 16, Núm. 1

  5. Gemcitabine. Gemzar®

    The Easy Book of Cancer Pharmacology (Nova Science Publishers, Inc.), pp. 197-205

  6. Growing teratoma syndrome: An unusual evolution of treated ovarian immature teratoma - A case report

    European Journal of Gynaecological Oncology, Vol. 37, Núm. 5, pp. 729-731

  7. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

  8. Long-Term Results of a Phase II Trial of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer

    International Journal of Gynecological Cancer, Vol. 26, Núm. 6, pp. 1162-1168

  9. Los estudios prospectivos de pacientes consecutivos con enfermedad tromboembólica venosa no identifican a todos los pacientes en riesgo: análisis multicéntrico ambispectivo del grupo ContaminaTEP

    Revista española de patología torácica, Vol. 28, Núm. 1, pp. 29-37

  10. Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 117, pp. 140-149

  11. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

  12. New concepts in cancer biomarkers: Circulating miRNAs in liquid biopsies

    International Journal of Molecular Sciences, Vol. 17, Núm. 5

  13. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

    Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89

  14. SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin

    Scientific Reports, Vol. 6

  15. Targeting SOX2 as a therapeutic strategy in glioblastoma

    Frontiers in Oncology

  16. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

  17. Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: The Spanish oncologic genitourinary group (SOGUG) SPAZO study

    Annals of Oncology, Vol. 27, Núm. 4, pp. 706-711